Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2014. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), and Connected Persons regarding their holdings in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
Transaction Details:
- Transaction Date: January 9, 2014
- Price per ADS: $52.8904
- Transaction Type: Re-investment of dividends paid to shareholders.
Material Changes
The filing reports increases in personal holdings for specific individuals due to dividend re-investment. No material changes to the company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory compliance notification regarding insider trading rules (Disclosure and Transparency Rules 3.1.4R(1)(a) and (c)).
Important Facts for Investors
- Dividend Re-investment: Several directors and PDMRs increased their ADS holdings on January 9, 2014, by re-investing dividends.
- Key Participants: Increases were recorded for Dr. M M Slaoui (997.193 ADSs), Mrs. D P Connelly (517.427 ADSs), Mr. D E Troy (303.467 ADSs), Dr. K Slaoui (16.644 ADSs), Mr. W C Louv (90.127 ADSs), and Mr. J Ford (0.090 ADSs).
- Notification Date: The company was advised of these transactions on January 16, 2014.
- No Financial Data: This filing contains no financial performance data for the company.